The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C10 | Lipid modifying agents | |
3 | C10B | Lipid modifying agents, combinations | |
4 | C10BX | Lipid modifying agents in combination with other drugs |
Code | Title | |
---|---|---|
C10BX01 | Simvastatin and acetylsalicylic acid | |
C10BX02 | Pravastatin and acetylsalicylic acid | |
C10BX03 | Atorvastatin and amlodipine | |
C10BX04 | ||
C10BX05 | ||
C10BX06 | ||
C10BX07 | ||
C10BX08 | ||
C10BX09 | ||
C10BX10 | ||
C10BX11 | ||
C10BX12 | ||
C10BX13 | ||
C10BX14 | ||
C10BX15 | ||
C10BX16 | ||
C10BX17 | ||
C10BX18 | ||
C10BX19 | ||
C10BX20 | ||
C10BX21 |
Active Ingredient | Description | |
---|---|---|
Atorvastatin and Amlodipine |
Combination of two drugs, a dihydropyridine calcium channel blocker, amlodipine, and an HMG-CoA reductase inhibitor, atorvastatin. The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. |
|
Atorvastatin and Perindopril |
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system). |
|
Atorvastatin, Amlodipine and Perindopril |
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. |
Title | Information Source | Document Type | |
---|---|---|---|
CADUET Film-coated tablet | Marketing Authorisation Holder | MPI, US: SPL/PLR | |
LIPERCOSYL Capsules, hard | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
TRIVERAM Film-coated tablet | Health Sciences Authority (SG) | MPI, EU: SmPC |